Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.

Campbell, David; Blazer, Marlo; Bloudek, Lisa; Brokars, John; Makenbaeva, Dinara

Campbell, David; Blazer, Marlo; Bloudek, Lisa; Brokars, John; Makenbaeva, Dinara.

Afiliación

Campbell D; Assistant Director, Scientific Consulting, Scientific Consulting, Xcenda, Palm Harbor, FL.
Blazer M; Associate Director, Scientific Consulting, Xcenda, Palm Harbor, FL.
Bloudek L; President, Curta, Seattle, WA.
Brokars J; Health Outcomes Research Director, Worldwide Health Economics and Outcomes Research Communications Lead, Bristol-Myers Squibb, Princeton, NJ.
Makenbaeva D; Group Director, Worldwide Health Economics and Outcomes Research Communications Lead, Bristol-Myers Squibb, Princeton, NJ.

Am Health Drug Benefits ; 12(7): 333-342, 2019 Nov.

Article en En | MEDLINE | ID: mdl-32055281

Palabras clave

chronic myelogenous leukemia (CML); cost-savings; formulary management; generic imatinib; pharmacy spending; prior authorization; step-edits; tyrosine kinase inhibitors (TKIs)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Health_economic_evaluation Idioma: En Revista: Am Health Drug Benefits Año: 2019 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google